APEIRON Biologics AG announced that it will present preclinical data for its clinical stage project APN401 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 26-30 October 2019 in Boston, MA, USA.
Vienna, Austria, 21 October 2019: APEIRON Biologics AG, a biotechnology company developing breakthrough cancer immunotherapies with an approved product on the market, announced today that it will present preclinical data for its clinical stage project APN401 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 26-30 October 2019 in Boston, MA, USA.
Poster: C048 - Novel master checkpoint Cbl-b siRNA-based adoptive cellular therapy: Superior anti-tumor efficacy in a syngeneic murine hepatocellular carcinoma Hepa1-6 model following APN401 monotherapy and synergistic effects with anti-PD1
Anderson Gaweco1, Kathrin Thell1, Maria Urban1, Julia Harrauer1, Isabella Haslinger1, Alexander Dohnal1, Guenther Lametschwandtner1, Karin Drobits1, Romana Gugenberger1, Hannes Muehleisen1, Josef Penninger2, Carlos Becerra3, Vincent Chung4, Anthony El-Khoueiry 5
1Apeiron Biologics; 2University of British Columbia; 3Baylor University Medical Center; 4City of Hope; 5USC Norris Comprehensive Cancer Center
Date: 29 October 2019
Session: Poster Session C: Therapeutic Agents—Other; 12:30 to 4:00pm
Room: Level 2, Hall D
About APEIRON Biologics AG
APEIRON is a privately-held European biotech company based in Vienna, Austria, focused on the discovery and development of novel cancer immunotherapies. APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in May 2017 for the treatment of pediatric neuroblastoma patients and out-licensed global, exclusive rights for this product to EUSA Pharma Ltd. APEIRON now leverages its proprietary master checkpoint blockade mechanism to enable the human body’s natural defense mechanisms to fight the tumor. APEIRON’s clinical lead program APN401 is a first-in-class autologous cellular therapy to strengthen immune reactivity via an intracellular master checkpoint, Cbl-b. APEIRON’s projects and technologies are bolstered by a strong patent portfolio. APEIRON’s development expertise is validated through partnerships with leading pharmaceutical companies and academic institutions.
For further information please contact:
APEIRON Biologics AG
Elis Karner, Investor and Public Relations
Email: investors@apeiron-biologics.
www.apeiron-biologics.com
Media and Investor Relations
MC Services AG
Raimund Gabriel
T +49 89 210 228 0
Email: apeiron@mc-services.eu
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of APEIRON as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
